Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone.
Yang
Scott H
SH
McNeely
Marguerite J
MJ
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced; D003937:Diagnosis, Differential; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced*; D008875:Middle Aged; D009127:Muscle Rigidity / Q000139:chemically induced / Q000175:diagnosis / Q000209:etiology; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology; D010195:Pancreatitis / Q000139:chemically induced*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D012206:Rhabdomyolysis / Q000139:chemically induced*; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone